Phages and antimicrobial proteins in the fight against antimicrobial resistance
INCATE catalyzes critical growth stage at Invitris
INCATE has selected Invitris as the first venture to receive €250,000 in “Stage II Funding” that will allow Invitris to complete spin-out from Chair of Physics of Synthetic Biological Systems at the Technical University of Munich (TUM) and further its mission to scale the production of phages, phage-derived and other antimicrobial proteins in the fight against antimicrobial resistance.
Symbolic image
Computer-generated image
Invitris was selected in INCATE stage I in January 2022 with advice being provided to support the scale of manufacturing and company founding. The team have built momentum since selection with key experiments to de-risk the fundamental science and opening of a new laboratory in the heart of Munich’s biotech ecosystem.
The INCATE selection committee was convinced by the dynamic team and the opportunity of a platform that can bring scalability to manufacturing of phages, endolysins, and other antimicrobial proteins. Phages in particular have potential to treat multi-drug resistant bacteria due to their ability to be tailored to the target disease. The funding allows Invitris to complete Technology Transfer from TUM and continue development toward a GMP ready process.
“INCATE stage I was integral to validating our technology and business model. We would not have been so well prepared to transfer out of an academic setting without INCATE. To be selected as the first team to win stage II is a confirmation of our potential to build a successful company.” – Patrick Grossmann, CEO Invitris GmbH
“We hope that Invitris will contribute to the social implementation of phage-related therapies as a breakthrough. In particular, we expect Invitris to dramatically improve flexibility, speed, quality control, and cost in the production process, and more importantly, to stimulate phage-related research activities.” Hideki Maki, INCATE Selection Committee member, Principal Scientist, Laboratory for Drug Discovery and Disease Research, Shionogi& Co.,Ltd.
This non-dilutive investment, ongoing advice from INCATE and further support including inclusion in the Winter ‘23 batch at Y Combinator will help Invitris to develop and scale an innovative platform technology that can have a significant impact on the fight against multidrug resistant infections.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.